MX368640B - Composición farmacéutica para tratar inflamación y dolor. - Google Patents

Composición farmacéutica para tratar inflamación y dolor.

Info

Publication number
MX368640B
MX368640B MX2014014816A MX2014014816A MX368640B MX 368640 B MX368640 B MX 368640B MX 2014014816 A MX2014014816 A MX 2014014816A MX 2014014816 A MX2014014816 A MX 2014014816A MX 368640 B MX368640 B MX 368640B
Authority
MX
Mexico
Prior art keywords
pain
pharmaceutical composition
treating inflammation
pharmaceutically acceptable
arylsulfonyl
Prior art date
Application number
MX2014014816A
Other languages
English (en)
Other versions
MX2014014816A (es
Inventor
P St Laurent Joseph
s jones Gerald
M Breese David
Original Assignee
Olatec Ind Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Olatec Ind Llc filed Critical Olatec Ind Llc
Publication of MX2014014816A publication Critical patent/MX2014014816A/es
Publication of MX368640B publication Critical patent/MX368640B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/275—Nitriles; Isonitriles
    • A61K31/277—Nitriles; Isonitriles having a ring, e.g. verapamil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/18—Sulfonamides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/32—Macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. carbomers, poly(meth)acrylates, or polyvinyl pyrrolidone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Neurology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Neurosurgery (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)

Abstract

La presente invención está dirigida a una composición farmacéutica que comprende un portador farmacéuticamente aceptable y un compuesto de ?-(arilsulfonil)alquilnitrilo, o una sal de éstos, farmacéuticamente aceptable. La presente invención también está dirigida a un método para el tratamiento de la inflamación, desórdenes relacionados con inflamación, o dolor, mediante la administración de un compuesto de ?-(arilsulfonil)alquilnitrilo o sus sales o solvatos farmacéuticamente aceptables, a un paciente que lo requiere.
MX2014014816A 2012-06-05 2013-06-04 Composición farmacéutica para tratar inflamación y dolor. MX368640B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261655916P 2012-06-05 2012-06-05
PCT/US2013/044157 WO2013184708A1 (en) 2012-06-05 2013-06-04 Pharmaceutical composition for treating inflammation and pain

Publications (2)

Publication Number Publication Date
MX2014014816A MX2014014816A (es) 2015-02-12
MX368640B true MX368640B (es) 2019-10-09

Family

ID=49671007

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014014816A MX368640B (es) 2012-06-05 2013-06-04 Composición farmacéutica para tratar inflamación y dolor.

Country Status (10)

Country Link
US (1) US20130324601A1 (es)
EP (1) EP2854785B1 (es)
JP (1) JP6208751B2 (es)
KR (1) KR20150023570A (es)
CN (1) CN104363902A (es)
AU (1) AU2013271778B2 (es)
BR (1) BR112014030287A2 (es)
CA (1) CA2875054A1 (es)
MX (1) MX368640B (es)
WO (1) WO2013184708A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9999610B2 (en) 2013-10-01 2018-06-19 Olatec Therapeutics Llc Pharmaceutical use of 3-benzylsulfonylpropionitrile
WO2015081188A1 (en) * 2013-11-27 2015-06-04 Olatec Industries Llc Pharmaceutical composition comprising omega-(arylsulfonyl)alkylnitrile
WO2015130595A1 (en) * 2014-02-25 2015-09-03 Olatec Industries Llc 4-benzylsulfonyl-2-butenenitrile

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3041155A1 (de) * 1980-10-31 1982-06-09 Bayer Ag, 5090 Leverkusen Verfahren zur herstellung von 2,3-dichlor-sulfonyl-acrylnitrilen
US5175192A (en) * 1984-03-19 1992-12-29 The Rockefeller University Inhibitors of the advanced glycosylation of proteins and methods of use therefor
US4996193A (en) * 1989-03-03 1991-02-26 The Regents Of The University Of California Combined topical and systemic method of administration of cyclosporine
US5959019A (en) * 1997-08-22 1999-09-28 Colgate-Palmolive Company Topical tale containing compositions
JP3873118B2 (ja) * 2001-12-19 2007-01-24 独立行政法人産業技術総合研究所 アリールスルホンの製造方法
WO2007103273A2 (en) * 2006-03-03 2007-09-13 Trustees Of Boston University Thioredoxin and thioredoxin reductase inhibitors
US20100221336A1 (en) * 2007-02-14 2010-09-02 Logical Therapeutics, Inc. Method of treating arthritis, pain or inflammation with naproxen 2(methanesulfonyl)ethyl ester and a proton pump inhibitor
AU2010226794A1 (en) * 2009-03-18 2011-10-27 Olatec Industries Llc Compounds for treating inflammation and pain
KR101849813B1 (ko) * 2010-12-15 2018-04-17 오라텍 세라퓨틱스 엘엘씨 염증 및 통증 치료용 3-메탄술포닐프로피오니트릴

Also Published As

Publication number Publication date
CN104363902A (zh) 2015-02-18
EP2854785A4 (en) 2016-02-10
AU2013271778B2 (en) 2018-03-01
CA2875054A1 (en) 2013-12-12
JP6208751B2 (ja) 2017-10-04
EP2854785A1 (en) 2015-04-08
US20130324601A1 (en) 2013-12-05
WO2013184708A1 (en) 2013-12-12
AU2013271778A1 (en) 2015-01-22
BR112014030287A2 (pt) 2017-06-27
EP2854785B1 (en) 2017-08-09
KR20150023570A (ko) 2015-03-05
MX2014014816A (es) 2015-02-12
JP2015518893A (ja) 2015-07-06

Similar Documents

Publication Publication Date Title
SA515360469B1 (ar) مركبات حلقية غير متجانسة لتثبيط إنزيم جلوتاميناز والطرق الخاصة باستخدامها
MY196418A (en) Therapeutically Active Compounds and Their Methods of use
MX365939B (es) Moduladores del transporte nuclear y usos de los mismos.
MX2015012850A (es) Inhibidores de la arginina metiltransferasa y usos de los mismos.
NZ710111A (en) Quinoline and quinoxaline amides as modulators of sodium channels
MX340090B (es) Analogos de spliceostatina.
IN2014DN09434A (es)
EA201690287A1 (ru) 1,4-дизамещенные аналоги пиридазин хинолина и способы лечения состояний, связанных с smn-дефицитом
MX345928B (es) Composiciones terapeuticamente activas y metodos de uso de las mismas.
MY188139A (en) Sodium channel modulators for the treatment of pain
MX2015010829A (es) Compuestos terapeuticos y sus usos.
MX2015016421A (es) Derivados de pirazolo-pirrolidin-4-ona como inhibidores de bet y su uso en el tratamiento de enfermedades.
MX2016004741A (es) Composicion farmaceutica que comprende un antagonista de trpa1 y un agente analgesico.
PH12015501088A1 (en) Dimeric compounds
MX2015016425A (es) Derivados de pirazolo-pirrolidin-4-ona y su uso en el tratamiento de enfermedades.
PH12016502352A1 (en) Pharmaceutical composition
EA032271B9 (ru) Вещества, фармацевтическая композиция и методы применения при лечении воспалительных заболеваний
AU2018253600A1 (en) Dosage forms and therapeutic uses of l-4-chlorokynurenine
MX2015013186A (es) Adminitracion craneal de productos farmaceuticos.
MX370898B (es) Agente terapéutico y/o preventivo que comprende un derivado de 1-indansulfamida para el dolor.
MX2014014814A (es) Composicion farmaceutica para el tratamiento de inflamacion y dolor.
NZ707636A (en) Ingenol-derived compounds that can be used for treating cancer
MX2014014816A (es) Composicion farmaceutica para tratar inflamacion y dolor.
MX362905B (es) Tratamiento de combinacion.
MX368641B (es) Compuestos para el tratamiento de inflamación y dolor.

Legal Events

Date Code Title Description
FG Grant or registration